Open access

Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report
Maxwell J Kroloff, Josefin-Beate Holz, Omer Stern, Christopher J Shepherd, Michelle Morrow, Louis Kayitalire, Deborah J Wong

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005225; DOI: 10.1136/jitc-2022-005225
CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein
Min Dong, Min Qian, Zhengyi Ruan

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005270; DOI: 10.1136/jitc-2022-005270
Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
Xia Liu, Fusheng Si, David Bagley, Feiya Ma, Yuanqin Zhang, Yan Tao, Emily Shaw, Guangyong Peng

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005020; DOI: 10.1136/jitc-2022-005020
Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization
Justin C Jagodinsky, Amber M Bates, Paul A Clark, Raghava N Sriramaneni, Thomas C Havighurst, Ishan Chakravarty, Erin J Nystuen, KyungMann Kim, Paul M Sondel, Won Jong Jin, Zachary S Morris

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005103; DOI: 10.1136/jitc-2022-005103
Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
Chengjie Xiong, Lihong Huang, Hedan Kou, Chenwei Wang, Xiaomin Zeng, Hanli Sun, Shangyuan Liu, Bin Wu, Jingyao Li, Xiaoling Wang, Zibing Wang, Lin Chen

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e004790; DOI: 10.1136/jitc-2022-004790
Ironing out exercise on immuno-oncological outcomes
Janjira Soh, Zi Xiang Lim, Elaine Hsuen Lim, Brian K Kennedy, Jorming Goh

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e002976; DOI: 10.1136/jitc-2021-002976
Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy
Laurent Dercle, Jeremy McGale, Shawn Sun, Aurelien Marabelle, Randy Yeh, Eric Deutsch, Fatima-Zohra Mokrane, Michael Farwell, Samy Ammari, Heiko Schoder, Binsheng Zhao, Lawrence H Schwartz

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005292; DOI: 10.1136/jitc-2022-005292
OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases
Michael Thiele, Seamas C Donnelly, Robert A Mitchell

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005475; DOI: 10.1136/jitc-2022-005475
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, Michael R Bishop, Daniel S Chen, Madhav Dhodapkar, Leisha A Emens, Marc S Ernstoff, Robert L Ferris, Tim F Greten, James L Gulley, Roy S Herbst, Rachel W Humphrey, James Larkin, Kim A Margolin, Luca Mazzarella, Suresh S Ramalingam, Meredith M Regan, Brian I Rini, Mario Sznol

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005413; DOI: 10.1136/jitc-2022-005413
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma
Georgia M Beasley, Michael C Brown, Norma E Farrow, Karenia Landa, Rami N Al-Rohil, Maria Angelica Selim, Aaron D Therien, Sin-Ho Jung, Junheng Gao, David Boczkowski, Eda K Holl, April K S Salama, Darell D Bigner, Matthias Gromeier, Smita K Nair

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005052; DOI: 10.1136/jitc-2022-005052

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages